High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus

Arthritis Research and Therapy

Volumn 13, Issue 3, 2011, Pages

  Abdulahad, Deena A ^a   Westra, Johanna ^a   Bijzet, Johannes ^a   Limburg, Pieter C ^a   Kallenberg, Cees G M ^a   Bijl, Marc ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIHIGH MOBILITY GROUP B1 PROTEIN ANTIBODY; C REACTIVE PROTEIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; HIGH MOBILITY GROUP B1 PROTEIN; UNCLASSIFIED DRUG; AUTOANTIBODY; DNA; IMMUNOGLOBULIN G;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; KIDNEY DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; PROTEINURIA; SEROLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; WESTERN BLOTTING; ACUTE DISEASE; ADOLESCENT; BLOOD; HOSPITALIZATION; IMMUNOLOGY; METABOLISM; METHODOLOGY; MIDDLE AGED;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AUTOANTIBODIES; BLOTTING, WESTERN; COMPLEMENT C3; COMPLEMENT C4; DNA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HMGB1 PROTEIN; HUMANS; IMMUNOGLOBULIN G; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 79955675740     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3332     Document Type: Article

References (42)

1. Shirai T, Hirose S. Molecular pathogenesis of SLE. Springer Semin Immunopathol 2006, 28:79-82. 10.1007/s00281-006-0032-5, 16941107.
2. Abdulahad DA, Westra J, Limburg PC, Kallenberg CG, Bijl M. HMGB1 in systemic lupus erythematosus: Its role in cutaneous lesions development. Autoimmun Rev 2010, 9:661-665. 10.1016/j.autrev.2010.05.015, 20546955.
3. Bergtold A, Gavhane A, D'Agati V, Madaio M, Clynes R. FcR-bearing myeloid cells are responsible for triggering murine lupus nephritis. J Immunol 2006, 177:7287-7295.
4. Schroeter AL, Conn DL, Jordon RE. Immunoglobulin and complement deposition in skin of rheumatoid arthritis and systemic lupus erythematosus patients. Ann Rheum Dis 1976, 35:321-326. 10.1136/ard.35.4.321, 1007389, 970989.
5. Tokumoto M, Fukuda K, Shinozaki M, Kashiwagi M, Katafuchi R, Yoshida T, Yanagida T, Kanai H, Hirakata H, Tamaki K, Okuda S, Fujishima M. Acute interstitial nephritis with immune complex deposition and MHC class II antigen presentation along the tubular basement membrane. Nephrol Dial Transplant 1999, 14:2210-2215. 10.1093/ndt/14.9.2210, 10489235.
6. Ehrenstein MR. Antinuclear antibodies and lupus: causes and consequences. Rheumatology (Oxford) 1999, 38:691-693.
7. Su Y, Jia RL, Han L, Li ZG. Role of anti-nucleosome antibody in the diagnosis of systemic lupus erythematosus. Clin Immunol 2007, 122:115-120. 10.1016/j.clim.2006.10.003, 17085075.
8. Baumann I, Kolowos W, Voll RE, Manger B, Gaipl U, Neuhuber WL, Kirchner T, Kalden JR, Herrmann M. Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum 2002, 46:191-201. 10.1002/1529-0131(200201)46:1<191::AID-ART10027>3.0.CO;2-K, 11817590.
9. Bijl M, Reefman E, Horst G, Limburg PC, Kallenberg CG. Reduced uptake of apoptotic cells by macrophages in systemic lupus erythematosus: correlates with decreased serum levels of complement. Ann Rheum Dis 2006, 65:57-63. 10.1136/ard.2005.035733, 1797975, 15919679.
10. Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994, 179:1317-1330. 10.1084/jem.179.4.1317, 2191465, 7511686.
11. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007, 81:1-5.
12. Harris HE, Raucci A. Alarmin(g) news about danger: workshop on innate danger signals and HMGB1. EMBO Rep 2006, 7:774-778. 1525157, 16858429.
13. Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E, Shelhamer JH, Suffredini AF. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 2003, 101:2652-2660. 10.1182/blood-2002-05-1300, 12456506.
14. Hreggvidsdottir HS, Ostberg T, Wahamaa H, Schierbeck H, Aveberger AC, Klevenvall L, Palmblad K, Ottosson L, Andersson U, Harris HE. The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation. J Leukoc Biol 2009, 86:655-662. 10.1189/jlb.0908548, 19564572.
15. Rendon-Mitchell B, Ochani M, Li J, Han J, Wang H, Yang H, Susarla S, Czura C, Mitchell RA, Chen G, Sama AE, Tracey KJ, Wang H. IFN-gamma induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. J Immunol 2003, 170:3890-3897.
16. Wahamaa H, Vallerskog T, Qin S, Lunderius C, LaRosa G, Andersson U, Harris HE. HMGB1-secreting capacity of multiple cell lineages revealed by a novel HMGB1 ELISPOT assay. J Leukoc Biol 2007, 81:129-136.
17. Wang H, Vishnubhakat JM, Bloom O, Zhang M, Ombrellino M, Sama A, Tracey KJ. Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes. Surgery 1999, 126:389-392. 10.1016/S0039-6060(99)70182-0, 10455911.
18. Bell CW, Jiang W, Reich CF, Pisetsky DS. The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol 2006, 291:C1318-C1325. 10.1152/ajpcell.00616.2005, 16855214.
19. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002, 418:191-195. 10.1038/nature00858, 12110890.
20. Kokkola R, Andersson A, Mullins G, Ostberg T, Treutiger CJ, Arnold B, Nawroth P, Andersson U, Harris RA, Harris HE. RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol 2005, 61:1-9. 10.1111/j.0300-9475.2005.01534.x, 15644117.
21. Yang H, Hreggvidsdottir HS, Palmblad K, Wang H, Ochani M, Li J, Lu B, Chavan S, Rosas-Ballina M, Al-Abed Y, Akira S, Bierhaus A, Erlandsson-Harris H, Andersson U, Tracey KJ. A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci USA 2010, 107:11942-11947. 10.1073/pnas.1003893107, 2900689, 20547845.
22. Park JS, Svetkauskatie D, He Q, Kim JY, Strassheim D, Ishizaka A, Abraham E. Involvement of Toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004, 279:7370-7377.
23. Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H, Parroche P, Drabic S, Golenbock D, Sirois C, Hua J, An LL, Audoly L, La Rosa G, Bierhaus A, Naworth P, Marshak-Rothstein A, Crow MK, Fitzgerald KA, Latz E, Kiener PA, Coyle AJ. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007, 8:487-496.
24. Ek M, Popovic K, Harris HE, Naucler CS, Wahren-Herlenius M. Increased extracellular levels of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in minor salivary glands of patients with Sjogren's syndrome. Arthritis Rheum 2006, 54:2289-2294. 10.1002/art.21969, 16802368.
25. Taira T, Matsuyama W, Mitsuyama H, Kawahara KI, Higashimoto I, Maruyama I, Osame M, Arimura K. Increased serum high mobility group box-1 level in Churg-Strauss syndrome. Clin Exp Immunol 2007, 148:241-247. 10.1111/j.1365-2249.2007.03347.x, 1868872, 17437420.
26. Taniguchi N, Kawahara K, Yone K, Hashiguchi T, Yamakuchi M, Goto M, Inoue K, Yamada S, Ijiri K, Matsunaga S, Nakajima T, Komiya S, Maruyama I. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum 2003, 48:971-981. 10.1002/art.10859, 12687539.
27. Urbonaviciute V, Furnrohr BG, Meister S, Munoz L, Heyder P, De Marchis F, Bianchi ME, Kirschning C, Wagner H, Manfredi AA, Kalden JR, Schett G, Rovere-Querini P, Herrmann M, Voll RE. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med 2008, 205:3007-3018. 10.1084/jem.20081165, 2605236, 19064698.
28. Hayashi A, Nagafuchi H, Ito I, Hirota K, Yoshida M, Ozaki S. Lupus antibodies to the HMGB1 chromosomal protein: epitope mapping and association with disease activity. Mod Rheumatol 2009, 19:283-292. 10.1007/s10165-009-0151-7, 19214652.
29. Li J, Xie H, Wen T, Liu H, Zhu W, Chen X. Expression of high mobility group box chromosomal protein 1 and its modulating effects on downstream cytokines in systemic lupus erythematosus. J Rheumatol 2010, 37:766-775. 10.3899/jrheum.090663, 20110525.
30. Kocsis AK, Szabolcs A, Hofner P, Takacs T, Farkas G, Boda K, Mandi Y. Plasma concentrations of high-mobility group box protein 1, soluble receptor for advanced glycation end-products and circulating DNA in patients with acute pancreatitis. Pancreatology 2009, 9:383-391. 10.1159/000181172, 19451748.
31. Wibisono D, Csernok E, Lamprecht P, Holle JU, Gross WL, Moosig F. Serum HMGB1 levels are increased in active Wegener's granulomatosis and differentiate between active forms of ANCA-associated vasculitis. Ann Rheum Dis 2010, 69:1888-1889. 10.1136/ard.2009.119172, 20542962.
32. Urbonaviciute V, Furnrohr BG, Weber C, Haslbeck M, Wilhelm S, Herrmann M, Voll RE. Factors masking HMGB1 in human serum and plasma. J Leukoc Biol 2007, 81:67-74.
33. Ma CY, Jiao YL, Zhang J, Yang QR, Zhang ZF, Shen YJ, Chen ZJ, Zhao YR. Elevated plasma level of HMGB1 is associated with disease activity and combined alterations with IFN-alpha and TNF-alpha in systemic lupus erythematosus. Rheumatol Int 2010, 10:1636-1636.
34. Hamada T, Torikai M, Kuwazuru A, Tanaka M, Horai N, Fukuda T, Yamada S, Nagayama S, Hashiguchi K, Sunahara N, Fukuzaki K, Nagata R, Komiya S, Maruyama I, Fukuda T, Abeyama K. Extracellular high mobility group box chromosomal protein 1 is a coupling factor for hypoxia and inflammation in arthritis. Arthritis Rheum 2008, 58:2675-2685. 10.1002/art.23729, 18759291.
35. Steenvoorden MM, Toes RE, Ronday HK, Huizinga TW, Degroot J. RAGE activation induces invasiveness of RA fibroblast-like synoviocytes in vitro. Clin Exp Rheumatol 2007, 25:740-742.
36. Zuo XX, Zhou YO, Gong YH, Wang YP, Tang DL, Xiao XZ. Expression of high mobility group box chromosomal protein 1 in peripheral blood of patients with rheumatoid arthritis. Zhonghua Nei Ke Za Zhi 2007, 46:547-550.
37. Bruchfeld A, Qureshi AR, Lindholm B, Barany P, Yang L, Stenvinkel P, Tracey KJ. High Mobility Group Box Protein-1 correlates with renal function in chronic kidney disease (CKD). Mol Med 2008, 14:109-115. 10.1007/s00894-007-0256-x, 2258159, 18317568.
38. Oyama Y, Hashiguchi T, Taniguchi N, Tancharoen S, Uchimura T, Biswas KK, Kawahara K, Nitanda T, Umekita Y, Lotz M, Maruyama I. High-mobility group box-1 protein promotes granulomatous nephritis in adenine-induced nephropathy. Lab Invest 2010, 90:853-866. 10.1038/labinvest.2010.64, 3096665, 20231821.
39. Qing X, Pitashny M, Thomas DB, Barrat FJ, Hogarth MP, Putterman C. Pathogenic anti-DNA antibodies modulate gene expression in mesangial cells: involvement of HMGB1 in anti-DNA antibody-induced renal injury. Immunol Lett 2008, 121:61-73. 10.1016/j.imlet.2008.08.007, 2677706, 18822317.
40. Bruchfeld A, Wendt M, Bratt J, Qureshi AR, Chavan S, Tracey KJ, Palmblad K, Gunnarsson I. High Mobility Group Box-1 protein (HMGB) is increased in antineutrophilic cytoplasmatic antibody (ANCA)-associated vasculitis with renal manifestations. Mol Med 2010, 17:29-35. 3022976, 20844833.
41. Sato F, Maruyama S, Hayashi H, Sakamoto I, Yamada S, Uchimura T, Morita Y, Ito Y, Yuzawa Y, Maruyama I, Matsuo S. High mobility group box chromosomal protein 1 in patients with renal diseases. Nephron Clin Pract 2008, 108:c194-c201. 10.1159/000118942, 18311084.
42. Mao SY, Xu Y, Zhang J, Schifferli K, An LL, Leininger J, Kiener P, Wu H, Coyle AJ, Audoly LP. Antagonizing HMGB1 inhibits proteinuria in a murine model of lupus like disease (abstract). J Immunol 2008, 178:131-124.